Acute myeloid leukemia (AML) patients are often characterized by deregulation of various intracellular signaling pathways, including PI3K/Akt/mTOR, which concur to increased cell proliferation and abnormal survival. Stagnation of clinical results, especially in patients not eligible for aggressive treatment, have prompted the investigation on novel targeted therapies. Currently, several PI3K/Akt/mTOR inhibitors, especially those targeting downstream signals, have been investigated in AML. However, reactivation of critical upstream nodes have been associated with reduced activity of these molecules. BKM120 is a novel pan-class I PI3K inhibitor, characterized by a significant cell growth inhibition and apoptosis in a variety of solid tumors. Therefore, we investigated preclinically the activity of BKM120 on several acute leukemia (AL) cell lines and on primary AML samples. BKM120, kindly provide by Novartis, was tested on different leukemia cell models (U937, HL60, MOLM13) and primary

PI3K inhibition by BKM120 on acute myeloid leukemia: a preclinical study / Allegretti, Matteo; Ricciardi, Maria Rosaria; Licchetta, Roberto; Mirabilii, Simone; M., Vincenzi; Foa, Roberto; Tafuri, Agostino. - In: HAEMATOLOGICA. - ISSN 0390-6078. - ELETTRONICO. - (2013). (Intervento presentato al convegno 44° Congresso Nazionale SIE tenutosi a Verona nel 20-23 Ottobre).

PI3K inhibition by BKM120 on acute myeloid leukemia: a preclinical study

ALLEGRETTI, MATTEO;RICCIARDI, Maria Rosaria;LICCHETTA, ROBERTO;MIRABILII, SIMONE;FOA, Roberto;TAFURI, Agostino
2013

Abstract

Acute myeloid leukemia (AML) patients are often characterized by deregulation of various intracellular signaling pathways, including PI3K/Akt/mTOR, which concur to increased cell proliferation and abnormal survival. Stagnation of clinical results, especially in patients not eligible for aggressive treatment, have prompted the investigation on novel targeted therapies. Currently, several PI3K/Akt/mTOR inhibitors, especially those targeting downstream signals, have been investigated in AML. However, reactivation of critical upstream nodes have been associated with reduced activity of these molecules. BKM120 is a novel pan-class I PI3K inhibitor, characterized by a significant cell growth inhibition and apoptosis in a variety of solid tumors. Therefore, we investigated preclinically the activity of BKM120 on several acute leukemia (AL) cell lines and on primary AML samples. BKM120, kindly provide by Novartis, was tested on different leukemia cell models (U937, HL60, MOLM13) and primary
2013
44° Congresso Nazionale SIE
04 Pubblicazione in atti di convegno::04d Abstract in atti di convegno
PI3K inhibition by BKM120 on acute myeloid leukemia: a preclinical study / Allegretti, Matteo; Ricciardi, Maria Rosaria; Licchetta, Roberto; Mirabilii, Simone; M., Vincenzi; Foa, Roberto; Tafuri, Agostino. - In: HAEMATOLOGICA. - ISSN 0390-6078. - ELETTRONICO. - (2013). (Intervento presentato al convegno 44° Congresso Nazionale SIE tenutosi a Verona nel 20-23 Ottobre).
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/542654
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact